“WE BELIEVE WE WILL OFFER IN A YEAR’S TIME A COMPLETE CURE FOR CANCER.” – Dan D. Aridor, Chairman of Accelerated Evolution Biotechnologies Ltd.
Greetings sports fans and welcome to yet another exciting episode of Vegas Vallet Sports Beat the little column that is still standing in spite of itself. It is bone-chillingly cold all across the United States as we go to press this afternoon. Reports are that the Chicago River and Niagra Falls are sheets of ice. But here in the beautiful Las Vegas Valley, the sun is shining bright and the only snow in sight is on top of Mount Charleston where it belongs.
Let us now turn our attention to matters of far greater import to Las Vegans and to humanity. To Israel where scientists say they ‘believe’ they will have a cure for cancer within a year’s time.
Having survived a congenital eye tumor and a cancerous tumor and kidney that was removed on October 4, 2017, this matter is of great import to me and I am pleased to have the privilege of bringing this news of great hope to you and your loved ones today.
Please keep in mind as you read the following article that the key word here is “believe.”
Company Chairman, Dan Aridor, said, “We believe in a years time we will have a complete cure for cancer.” This coming under the capable leadership of, Dr. Ilan Morad the Chief Executive Officer of AEBi, and their Chief Science Officer, Dr. Hinan Itzhaki.
AEBi’s claim seems more than just a little optimistic in light of the fact that cancer is the cause of one in every six deaths worldwide. It is now the second leading cause of death on earth, with cardiovascular disease holding on fast at number one.
If Dr. Morad has it his way cancer will be effectively eliminated from that list all together within the span of a years time. And by George, I believe he’s got it.
Unlike other companies who are engaged in similar research within the ‘Phage family’ AEBi states that their new platform is unique in that it provides their scientists with “Functional leads to very difficult targets” ( Agonist, antagonist, inhibitor, and so forth.) rather than those that do no more than bind with the target the best.
The potential new drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences, and small molecules.
In the year 2000, Dr. Morad came up with an idea of how to formulate what could be described as a functional Phage Display. * Just six years later, he was able to prove that AEBi’s innovative technology, which they call “SoAP” truly does work.
“We were doing what everyone else was doing, trying to discover individual novel peptides for specific cancers.” But Dr. Morad and Dr. Itzhaki decided that they needed to move in another direction. They were on to something far bigger and better by far.
First, they had to discover the reasons why other cancer drugs and treatments either fail in the long term or they do not work at all. Once that hurdle was cleared they searched for and found a way to counteract those effects.
Established in 2000, AEBi has since been managed upon the theory that the ability to design and manipulate peptides gives them far greater advantages over many drug development technologies.
The basic premise is that AEBi does not need a natural lead which typically comes from research and through academicians. Those they say are not strong enough nor specific enough to work with effectively and are difficult for scientists to manipulate when attempting to create new medicines that are smaller, cheaper, easier to produce, and easier to regulate.
YOU SAY MuTaTo, I SAY MuTaTo. LET’S KILL THE WHOLE THING OFF.
The new treatment, which AEBi calls MuTaTo ( Multi-Target Toxin), will utilize a cocktail of peptides which are compounds of two or more amino acids linked in a chain. Those peptides which target cancer cells will be combined with a specific toxin that will then kill the targeted cancer cells.
MuTaTo is basically a type of target-specific poison for cancerous cells. Or what, AEBI describes as “A disruptive technology of the highest order.”
The majority of drugs attack a specific target either on or in the cancer cell itself. These drugs then inhibit the targeted cells affecting a physiological pathway which contributes to the growth of cancer cells.
Many cytoxins* used for treating cancer are aimed at the fast-growing cells but cancer stem cells are not fast-growing and are capable of evading such treatments. Mutations either within the target cells or along those physiological pathways could effectively make the targets irrelevant to the cancerous nature of the targeted cells. In turn, the drugs attacking the disease are typically rendered ineffective to stop the progression of cancer in those cells.
Many cancer cells also have built-in detoxification mechanisms that can become activated by stressors that originate from the treatment drugs themselves. These mechanisms then eliminate those drugs or cause cellular modifications that make them non-functional.
“But detoxification takes time.” Dr. Morad said. Thus whenever the toxin is strong it is likely it will kill the targeted cells before any such detoxification can occur. This is what AEBi believes in. That is what the world is counting on.
Certain malignant tumors put up barriers creating problems for large molecules such as antibodies. According to AEBi, MuTaTo works much like multiple strands of spaghetti or an octopus. Their multiple tendrils can reach down into places that larger molecules cannot reach. The peptides found in MuTaTo are very tiny and lack rigid structure.
“If it does not completely annihilate the cancer, the remaining cells can start to get mutations again, and then the cancer comes back, but this time it is drug resistant,” Morad then explained that because cancer cells are born from mutations occuring in cancer stem cells. Most of the overexpressed proteins which are targeted on the cancer cell exist in the cancer stem cells. MuTaTo’s multiple-target attack ensures that they will be destroyed as well.
“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” “Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
“By using at least three targeting peptides on the same structure with a strong toxin, We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer. The treatment will eventually be personalized and a specific cocktail of the drugs will be given to patients based on their type of cancer. This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug,” ” Dr. Morad told the Jerusalem Post.
It seems likely that AEBi’s discovery may also reduce the side-effects of many treatments that traditionally cause lasting illness in patients. These stem from the interaction of those drug treatments with the wrong/individual targets. This also occurs when the targeted cells are correct but are not cancerous.
MuTaTo will consist of a combination of highly specific cancer-targeting peptides. Each specific type of cancerous cell thus having a single scaffold will increase the specific focus of the attack on the targeted cells due to the avidity effect Additionally, in most cases, non-cancerous cells that share a protein common to the cancerous cells do not overexpress it.
As Dr. Morad stated it, “This makes a great difference between the two kinds of cells and should decrease the side effects dramatically,”
The MuTaTo treatment will be personalized for each patient who will provide a laboratory with a section of their biopsy. This sample would be analyzed to discover which receptors are overexpressed in the individuals’ cells and the patient would then be administered the precise combination of peptides and cytoxins needed to cure his or her cancer. The cancerous cells would be eliminated permanently, and the patient should be able to discontinue their treatment after several weeks.
“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”
Believe it and achieve it. Works every time.
Dr. Ilan Morad
Dan D. Aridor Chairman of the Board -Accelerated Evolution Biotechnologies Ltd. (AEBi)
Dr. Ilan Morad Ph.D. Founder and CEO – AEBi
Dr. Hinan Itzhaki Ph.D. Chief Science Officer – AEBi
Affinity and Avidity of Antibodies https://www.bio-rad-antibodies.com/antigen-antibody-interactions.html
Cytoxins generally. Cytotoxicity is the quality of being toxic to cells. Examples of toxic agents are an immune cell or some types of venom, e.g. from the puff adder (Bitis arietans) or brown recluse spider (Loxosceles reclusa). https://en.wikipedia.org/wiki/Cytotoxicity
MeSH Descriptor Data 2019 https://meshb.nlm.nih.gov/record/ui?name=Cytotoxins
The American Cancer Society https://www.cancer.org/
Cancer Screening Guidelines By Age https://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/screening-recommendations-by-age.html
World Health Organization- Early Detection of Cancer https://www.who.int/cancer/detection/en/
The MuTaTo cancer